〔Abstract〕 Objective To explore the immunologic signature genes(ISGs) associated with cisplatin resistance in gastric cancer based on gene set enrichment analysis(GSEA). Methods GSE94714 dataset from GEO database was used, and the differentially expressed genes(DEGs) were analyzed with GEO2 R. The effects of conditional gene screening on gene number were observed. GSEA included all DEGs from gastric cancer cells in drug resistant and non-resistant groups. The DEGs were compared with the molecular signatures database(MSigDB), and the obtained ISGs were screened for intersection, and the effects of ISGs on the prognosis of gastric cancer were analyzed by Kaplan Meier Plotter method. Results A total of 34 183 DEGs included 12 452 up-regulated and 17 381 down-regulated genes. The increased fold change(FC) added the number of excluded genes. Six entries with the top normalized enrichment score(NES) were identified by GSEA(P<0.01). The intersection ISGs included mitochondrial ribosomal protein L 12(MRPL12), proline-rich protein 13(PRR13), coactosin like F-actin binding protein 1(COTL1), poly(RC) binding protein 1(PCBP1), iduronate 2-sulfatase(IDS), LIM domain containing 2(LIMD2), purine rich element binding protein A(PURA), small optic lobes homolog(SOLH), CCR4-NOT transcription complex subunit 3(CNOT3), transforming growth factor beta 1(TGFβ1), diacylglycerol kinase zeta(DGKZ), and docking protein 2(DOK2). Twelve ISGs were associated with the overall survival time of gastric cancer, all of which were statistically significant(P<0.05). Conclusion The GSEA method can effectively extract the ISGs of cisplatin resistance in gastric cancer. Newly discovered ISGs, as potential targets, can enhance the study of chemoresistant mechanisms in gastric cancer.